Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
RARE on Nasdaq
Shares outstanding
95,963,102
Price per share
$23.00
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
95,480,234
Total reported value
$2,872,312,808
% of total 13F portfolios
0.01%
Share change
+593,699
Value change
-$30,046,954
Number of holders
296
Price from insider filings
$23.00
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 8.3% $239,585,319 7,964,937 FMR LLC 30 Sep 2025
BlackRock, Inc. 5.1% $183,098,959 4,820,931 BlackRock, Inc. 31 Mar 2025
SANDS CAPITAL MANAGEMENT, LLC 4.7% $163,238,154 4,298,003 SANDS CAPITAL MANAGEMENT, LLC 31 Dec 2024
WELLINGTON MANAGEMENT GROUP LLP 2.7% $93,337,483 2,457,543 Wellington Management Group LLP 31 Dec 2024

As of 30 Sep 2025, 296 institutional investors reported holding 95,480,234 shares of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE). This represents 99% of the company’s total 95,963,102 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) together control 68% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 11% 10,132,728 -0.79% 0% $304,792,459
FMR LLC 7.6% 7,283,296 +180% 0.01% $219,081,558
BlackRock, Inc. 6.7% 6,425,263 +2.7% 0% $193,271,911
JPMORGAN CHASE & CO 4.2% 4,011,429 +23% 0.01% $120,663,796
SANDS CAPITAL MANAGEMENT, LLC 3.9% 3,769,853 -4.4% 0.31% $113,397,178
STATE STREET CORP 3.8% 3,692,487 +44% 0% $111,070,009
RTW INVESTMENTS, LP 3.4% 3,258,266 +91% 1.2% $98,008,641
BAKER BROS. ADVISORS LP 2.9% 2,772,692 0% 0.6% $83,402,575
PRICE T ROWE ASSOCIATES INC /MD/ 2.4% 2,310,174 -20% 0.01% $69,491,000
JACOBS LEVY EQUITY MANAGEMENT, INC 2.3% 2,167,729 +614% 0.26% $65,205,288
SUVRETTA CAPITAL MANAGEMENT, LLC 2.1% 2,019,000 -11% 1.8% $60,731,520
WELLINGTON MANAGEMENT GROUP LLP 2% 1,945,129 +3.9% 0.01% $58,509,481
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,580,507 -7.7% 0% $47,551,518
DEUTSCHE BANK AG\ 1.6% 1,546,101 -7.2% 0.02% $46,506,718
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.6% 1,545,279 +6.4% 0.12% $46,482,000
Pictet Asset Management Holding SA 1.5% 1,458,187 -14% 0.04% $43,988,784
Rock Springs Capital Management LP 1.3% 1,246,341 -10% 2.2% $37,489,937
GW&K Investment Management, LLC 1.2% 1,150,169 +139% 0.31% $34,597,000
Schonfeld Strategic Advisors LLC 1.2% 1,144,589 +102% 0.24% $34,429,232
FRONTIER CAPITAL MANAGEMENT CO LLC 1.1% 1,069,098 +103% 0.29% $32,158,463
Frazier Life Sciences Management, L.P. 1% 983,715 0% 0.89% $29,590,147
Aberdeen Group plc 1% 973,656 +94% 0.05% $29,287,572
MORGAN STANLEY 0.95% 910,183 +42% 0% $27,378,343
Russell Investments Group, Ltd. 0.88% 840,451 +599% 0.03% $25,280,799
Invesco Ltd. 0.83% 794,849 +9.8% 0% $23,909,058

Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 2,189,482 $50,320,060 +$2,731,931 $23.00 17
2025 Q3 95,480,234 $2,872,312,808 -$30,046,954 $30.08 296
2025 Q2 94,131,376 $3,423,160,510 +$191,188,547 $36.36 307
2025 Q1 88,841,861 $3,218,915,813 +$30,616,617 $36.21 297
2024 Q4 87,497,812 $3,681,153,433 +$1,949,206 $42.07 309
2024 Q3 86,896,233 $4,824,969,188 -$72,319,917 $55.55 299
2024 Q2 88,212,580 $3,625,598,894 +$337,028,289 $41.10 273
2024 Q1 79,925,459 $3,729,060,008 -$19,184,689 $46.69 268
2023 Q4 80,397,353 $3,844,802,509 +$498,492,380 $47.82 236
2023 Q3 70,612,041 $2,517,056,820 +$10,459,486 $35.65 219
2023 Q2 69,514,116 $3,206,303,623 +$38,331,356 $46.13 239
2023 Q1 68,735,803 $2,755,924,776 +$28,159,264 $40.10 227
2022 Q4 68,068,127 $3,153,029,340 +$13,205,113 $46.33 225
2022 Q3 67,920,512 $2,812,302,784 -$149,070,496 $41.41 223
2022 Q2 67,540,585 $4,030,154,883 +$24,063,212 $59.66 210
2022 Q1 67,087,441 $4,870,684,649 -$37,258,962 $72.62 227
2021 Q4 67,646,883 $5,688,385,130 +$80,515,709 $84.09 224
2021 Q3 66,666,465 $6,012,124,489 +$97,920,619 $90.19 217
2021 Q2 65,481,898 $6,240,143,536 -$246,149,121 $95.35 235
2021 Q1 67,877,270 $7,730,039,829 +$45,641,218 $113.86 244
2020 Q4 67,658,657 $9,366,525,048 +$640,902,584 $138.43 247
2020 Q3 63,092,193 $5,187,430,003 -$8,503,385 $82.19 199
2020 Q2 63,208,158 $4,944,359,312 +$242,670,060 $78.22 185
2020 Q1 60,196,473 $2,674,187,064 +$87,973,460 $44.43 166
2019 Q4 57,960,233 $2,475,997,749 -$30,518,994 $42.71 162
2019 Q3 58,743,550 $2,513,000,802 -$3,746,657 $42.78 164
2019 Q2 58,918,990 $3,740,916,935 +$48,975,164 $63.50 165
2019 Q1 58,332,415 $4,045,800,203 +$544,963,218 $69.36 170
2018 Q4 50,637,251 $2,201,420,429 -$8,455,097 $43.48 155
2018 Q3 49,753,360 $3,798,517,088 +$72,495,753 $76.34 171
2018 Q2 48,810,187 $3,751,960,915 +$16,214,593 $76.87 151
2018 Q1 48,941,898 $2,495,515,451 +$366,583,930 $50.99 159
2017 Q4 43,222,558 $2,004,746,148 +$107,302,956 $46.38 154
2017 Q3 40,596,743 $2,164,481,778 -$37,427,143 $53.26 148
2017 Q2 41,247,736 $2,557,116,579 +$26,416,443 $62.11 154
2017 Q1 40,725,846 $2,759,699,220 +$146,474,004 $67.78 160
2016 Q4 41,627,417 $2,926,846,973 +$146,410,374 $70.31 172
2016 Q3 39,527,653 $2,802,274,760 +$175,377,803 $70.94 167
2016 Q2 36,785,323 $1,799,227,912 -$45,286,683 $48.91 153
2016 Q1 37,365,438 $2,365,011,412 +$86,675,812 $63.31 159
2015 Q4 35,576,368 $3,991,057,622 +$35,682,868 $112.18 165
2015 Q3 35,309,662 $3,400,791,001 +$270,511,040 $96.31 156
2015 Q2 32,519,914 $3,330,261,876 +$95,161,030 $102.39 150
2015 Q1 31,628,609 $1,962,983,846 +$227,346,470 $62.09 126
2014 Q4 27,930,073 $1,225,534,642 +$58,809,022 $43.88 98
2014 Q3 26,496,419 $1,499,696,849 +$542,429,017 $56.60 98
2014 Q2 16,922,876 $747,921,361 +$55,850,290 $44.89 81
2014 Q1 15,678,184 $746,820,000 +$746,820,000 $48.89 77